phase 3 trials of atezolizumab versus standard chemotherapy in pd-l1-selected nsclc
Published 8 years ago • 366 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
4:18
impower110: atezolizumab vs chemo in pd-l1–selected nsclc
-
1:12
cityscape: 1l tiragolumab atezolizumab vs placebo atezolizumab in pd-l1-selected nsclc
-
5:10
results from a phase 3 study of 1l atezolizumab vs single-agent chemotherapy in pts with nsclc
-
6:20
atezolizumab for locally advanced or metastatic pd-l1-selected nsclc
-
2:52
pd-l1 and tmb as biomarkers in the imvigor211 trial of atezolizumab vs. chemo for bladder cancer
-
6:09
impower010: a phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy ...
-
4:00
birch: phase 2 trial of atezolizumab for advanced pd-l1-selected non-small cell lung cancer
-
3:46
phase iii trial: pembrolizumab for patients w/ metastatic nsclc that expresses pd-1
-
7:20
new phase 3 data on pd-l1 vs. chemotherapy for first-line nsclc
-
6:06
atezolizumab monotherapy vs docetaxel in 2nd and 3rd line nsclc
-
5:05
anti–pd-l1 atezolizumab or chemotherapy as second-line therapy in patients with sclc
-
2:15
dr. wakelee on birch trial for atezolizumab in patients with nsclc
-
1:41
adjuvant atezolizumab in nsclc
-
1:50
pd-l1 agents in the treatment of nsclc
-
3:17
impower010: os results of atezolizumab vs best supportive care in resected nsclc
-
1:27
fda approval of atezolizumab for nsclc
-
3:27
#esmo21 highlights on patterns of relapse in nsclc to atezolizumab vs bsc after adj ct: impower010
-
3:46
phase iii trial: pembrolizumab for patients w/ metastatic nsclc that expresses pd-1
-
8:20
impower010: atezolizumab versus best supportive care after adjuvant chemotherapy in resected nsclc